{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Lu WH"],"funding":["Pierre Fabre Research Institute","NIA NIH HHS","French Ministry of Health","National Institute on Aging","INSERM-University of Toulouse III UMR 1027 Unit","Avid Radiopharmaceuticals Inc.","Region Occitanie/Pyrénées-Méditerranée","Centre Hospitalier Universitaire de Toulouse","Alzheimer Prevention in Occitania and Catalonia","ExonHit Therapeutics SA","Gérontopôle of Toulouse","Institutional gift funds","Association Monegasque pour la Recherche sur la maladie d’Alzheimer","EUR CARe","Institutional startup funds","European Regional Development Fund"],"pagination":["1489-1503"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9213609"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["44(3)"],"pubmed_abstract":["We investigated combining a core AD neuropathology measure (plasma amyloid-beta [Aβ] <sub>42/40</sub>) with five plasma markers of inflammation, cellular stress, and neurodegeneration to predict cognitive decline. Among 401 participants free of dementia (median [IQR] age, 76 [73-80] years) from the Multidomain Alzheimer Preventive Trial (MAPT), 28 (7.0%) participants developed dementia, and 137 (34.2%) had worsening of clinical dementia rating (CDR) scale over 4 years. In the models utilizing plasma Aβ alone, a tenfold increased risk of incident dementia (nonsignificant) and a fivefold increased risk of worsening CDR were observed as each nature log unit increased in plasma Aβ levels. Models incorporating Aβ plus multiple plasma biomarkers performed similarly to models included Aβ alone in"],"journal":["GeroScience"],"pubmed_title":["Investigating the combination of plasma amyloid-beta and geroscience biomarkers on the incidence of clinically meaningful cognitive decline in older adults."],"pmcid":["PMC9213609"],"funding_grant_id":["2009","ANR-18-EURE-0003","1901175","PHRC 2008","MP0022856","RF1 AG061900","NIH R56AG061900","RF1AG061900"],"pubmed_authors":["Dantoine T","Vellas B","Villars H","Burdet C","Belleville S","Willebois S","Rouaud O","Gervais C","Gonfrier S","Payoux P","Dupuy C","Lapoujade B","Cotton F","Faisant C","Dubois D","Bonafe A","Dartigues JF","Zanca M","Fontaine F","Tong MLY","Zueras A","Costes C","Livet P","Lehericy S","Darcourt J","Caillaud C","Nguyen AD","Parini A","Derumeaux H","Malick-Loiseau C","Bernard-Bourzeix L","Chollet F","Brigitte L","Franon E","Picat MA","Vinel C","de Souto Barreto P","Lala F","Cognard C","Chanalet S","Rolland Y","Mangin JF","Hugon F","Abellan Van Kan G","Blatge C","Bordes S","Begorre D","Bouhayia A","Pader ML","Pays C","Clement JP","Guyonnet S","Marcet I","Dufouil C","Desclaux F","Cardinaud N","Basset MF","Louchart S","Gedeon C","Hitzel A","Costa N","Bennys K","Voisin T","Andrieu S","Faure V","Combrouze E","Martel MPB","Cuffi MN","Bateman RJ","Chupin M","Molinier L","Coley N","Bonnefoy M","Ousset PJ","Laubarie-Mouret C","Perret B","Delrieu J","Cazaban-Campistron E","Idrissi SME","Quipourt V","Robert P","Skolil P","Touati L","Cantet C","Terracol F","Gilbert B","Carrie I","Ricolfi F","Willis S","Romano A","Marelli C","Cerda S","Lefebvre JF","Aggarwal G","Carpuat C","Li Y","Monteil J","Marilier S","Roth S","Sudres K","Gasnier Y","Foubert A","Gabelle A","Touchon J","Olivier-Abbal P","Manckoundia P","Lu WH","Rebaudet P","Badufle C","Pesce A","Caspar-Bauguil S","Bonneville F","Desormais I","Delva F","Lebrun N","Peiffer S","Morin C","Bories L","Saulnier I","Khales K","Barro-Belaygues N","Le Duff F","Chaillou S","Giudici KV","Salles JP","Morley JE","MAPT/DSA Group","Allard M"],"additional_accession":[]},"is_claimable":false,"name":"Investigating the combination of plasma amyloid-beta and geroscience biomarkers on the incidence of clinically meaningful cognitive decline in older adults.","description":"We investigated combining a core AD neuropathology measure (plasma amyloid-beta [Aβ] <sub>42/40</sub>) with five plasma markers of inflammation, cellular stress, and neurodegeneration to predict cognitive decline. Among 401 participants free of dementia (median [IQR] age, 76 [73-80] years) from the Multidomain Alzheimer Preventive Trial (MAPT), 28 (7.0%) participants developed dementia, and 137 (34.2%) had worsening of clinical dementia rating (CDR) scale over 4 years. In the models utilizing plasma Aβ alone, a tenfold increased risk of incident dementia (nonsignificant) and a fivefold increased risk of worsening CDR were observed as each nature log unit increased in plasma Aβ levels. Models incorporating Aβ plus multiple plasma biomarkers performed similarly to models included Aβ alone in","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Jun","modification":"2026-05-27T20:28:34.923Z","creation":"2025-02-19T02:44:01.788Z"},"accession":"S-EPMC9213609","cross_references":{"pubmed":["35445358"],"doi":["10.1007/s11357-022-00554-y"]}}